Junho Chung

Title: Innovations of Junho Chung in Antibody Development

Introduction

Junho Chung is a notable inventor based in Gyeongsangbuk-do, South Korea. He has made significant contributions to the field of biotechnology, particularly in the development of humanized antibodies. His work focuses on creating innovative solutions for medical challenges, especially in the treatment of diseases such as cancer.

Latest Patents

Junho Chung holds a patent for an "Anti-HGF/SF humanized antibody." This inventive antibody is prepared by displaying on the surface of a phage an anti-HGF/SF chimeric Fab library. The library comprises a set of human antibody light chain variable regions and human antibody heavy chain variable regions, which are grafted with heavy chain complementary determining regions of an anti-HGF/SF antibody from an animal other than human. This innovative antibody exhibits equal or greater binding affinity than that of the parent anti-HGF/SF antibody. It also possesses neutralizing activity that inhibits the binding of HGF/SF to its receptor, cMET, while having reduced immunogenicity in humans. Therefore, this humanized antibody can be effectively used for preventing and treating diseases, such as cancers, by binding HGF/SF to cMET.

Career Highlights

Junho Chung is currently associated with Abxign, Inc., where he continues to advance his research and development efforts. His work at the company emphasizes the importance of innovative therapeutic solutions in the medical field.

Collaborations

Junho Chung collaborates with Kisu Kim, contributing to the advancement of their shared research goals. Their partnership enhances the potential for breakthroughs in antibody development.

Conclusion

Junho Chung's innovative work in the field of humanized antibodies represents a significant advancement in biotechnology. His contributions have the potential to lead to effective treatments for serious diseases, showcasing the importance of innovation in healthcare.